- Home
- DJCO vs CTNM Comparison
DJCO vs CTNM Comparison
Compare DJCO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DJCO | CTNM |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 575.3M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | DJCO | CTNM |
|---|---|---|
| Price | $522.97 | $15.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 72.6K | ★ 197.4K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $348.63 | $3.35 |
| 52 Week High | $674.75 | $16.33 |
Technical Indicators
Market Signals| Indicator | DJCO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 60.91 |
| Support Level | $383.43 | $10.17 |
| Resistance Level | $674.75 | $16.01 |
| Average True Range (ATR) | 39.28 | 0.88 |
| MACD | -2.58 | -0.05 |
| Stochastic Oscillator | 53.80 | 70.04 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.